Business Daily Media

Men's Weekly

.

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

  • Written by ACN Newswire - Press Releases

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

TOKYO, Oct 16, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years

Read more //?#

AIIMS Group and AdVisible merge

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience     ...

Block's layoffs are a design win. Here's why

We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...

Why I Decided to Build a Better Way to Build Homes

Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...

Leonardo.Ai reveals new brand, expanding its creator-first platform for the next era of generative AI

The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...

Psychosocial injury risk starts inside workplace microcultures

Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...

2025 Thryv Business and Consumer Report - Australian small businesses show grit under pressure

Australia’s small businesses are powering ahead with optimism, resilience and discipline, however, mounting pressures on costs, wellbeing and cons...